Effect of prophylactic palivizumab on admission due to respiratory syncytial virus infection in former very low birth weight infants with bronchopulmonary dysplasia

Journal of Korean Medical Science

Volumn 30, Issue 7, 2015, Pages 924-931

  Han, Young Mi ^a   Seo, Hyun Joo ^b   Choi, Seo Heui ^c   Jung, Yu Jin ^d   Ahn, So Yoon ^c   Yoo, Hye Soo ^c   Sung, Se In ^c   Shim, Jae Won ^e   Lee, Yeon Kyung ^f   Ko, Sun Young ^f   Shin, Son Moon ^f   Hwang, Jong Hee ^g   Lee, Jang Hoon ^h   Choi, Byung Min ⁱ   Kim, Eun Sun ^j   Jeon, Ji Hyun ^j   Kim, Sung Shin ^k   Chang, Yun Sil ^c   Park, Won Soon ^c  

^a Pusan National University School of Medicine   (South Korea)

^b Seoul Medical Center   (South Korea)

^c Sungkyunkwan University School of Medicine   (South Korea)

^d Inje University College of Medicine   (South Korea)

^e School of Medicine   (South Korea)

^f Dankook University   (South Korea)

^g Inje University   (South Korea)

^h Ajou University School of Medicine   (South Korea)

ⁱ Korea University College of Medicine   (South Korea)

^j Kangwon National University   (South Korea)

^k Soonchunhyang University College of Medicine   (South Korea)

more..

Author keywords

Bronchopulmonary dysplasia; Hospitalization; Infant; Palivizumab; Preterm; Respiratory syncytial viruses

Indexed keywords

ANTIVIRUS AGENT; PALIVIZUMAB;

ANTIBIOTIC PROPHYLAXIS; BIRTH WEIGHT; CLINICAL TRIAL; COMPLICATION; DRUG EFFECTS; FEMALE; GESTATIONAL AGE; HOSPITALIZATION; HUMAN; HUMAN RESPIRATORY SYNCYTIAL VIRUS; INFANT; LENGTH OF STAY; LUNG DYSPLASIA; MALE; MULTICENTER STUDY; NEWBORN; PREMATURITY; PROCEDURES; PROSPECTIVE STUDY; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RISK; RISK FACTOR; STATISTICS AND NUMERICAL DATA; VERY LOW BIRTH WEIGHT;

ANTIBIOTIC PROPHYLAXIS; ANTIVIRAL AGENTS; BIRTH WEIGHT; BRONCHOPULMONARY DYSPLASIA; FEMALE; GESTATIONAL AGE; HOSPITALIZATION; HUMANS; INFANT; INFANT, NEWBORN; INFANT, PREMATURE; INFANT, VERY LOW BIRTH WEIGHT; LENGTH OF STAY; MALE; PALIVIZUMAB; PROSPECTIVE STUDIES; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUSES; RISK; RISK FACTORS;

EID: 84951772545     PISSN: 10118934     EISSN: 15986357     Source Type: Journal    
DOI: 10.3346/jkms.2015.30.7.924     Document Type: Article

References (29)

1. Reiss I, Landmann E, Heckmann M, Misselwitz B, Gortner L. Increased risk of bronchopulmonary dysplasia and increased mortality in very preterm infants being small for gestational age. Arch Gynecol Obstet 2003; 269: 40-4.
2. Bancalari E, Claure N, Sosenko IR. Bronchopulmonary dysplasia: changes in pathogenesis, epidemiology and definition. Semin Neonatol 2003; 8: 63-71.
3. McCormick MC, Shapiro S, Starfield BH. Rehospitalization in the first year of life for high-risk survivors. Pediatrics 1980; 66: 991-9.
4. Morris BH, Gard CC, Kennedy K, NICHD Neonatal Research Network. Rehospitalization of extremely low birth weight (ELBW) infants: are there racial/ethnic disparities? J Perinatol 2005; 25: 656-63.
5. Lamarche-Vadel A, Blondel B, Truffer P, Burguet A, Cambonie G, Selton D, Arnaud C, Lardennois C, du Mazaubrun C, N'Guyen S, et al.; EPIPAGE Study Group. Re-hospitalization in infants younger than 29 weeks' gestation in the EPIPAGE cohort. Acta Paediatr 2004; 93: 1340-5.
6. Hack M, DeMonterice D, Merkatz IR, Jones P, Fanaroff AA. Rehospitalization of the very-low-birth-weight infant. A continuum of perinatal and environmental morbidity. Am J Dis Child 1981; 135: 263-6.
7. Cunningham CK, McMillan JA, Gross SJ. Rehospitalization for respiratory illness in infants of less than 32 weeks' gestation. Pediatrics 1991; 88: 527-32.
8. Elder DE, Hagan R, Evans SF, Benninger HR, French NP. Hospital admissions in the first year of life in very preterm infants. J Paediatr Child Health 1999; 35: 145-50.
9. Kim SJ, Chae SH, Lee JH, Kim YJ, Koo SH, Jeon GW, Chang YS, Park WS. Rehospitalization of very low birth weight infants in first year after discharge from NICU and risk factor of rehospitalization caused by respiratory illness. J Korean Soc Neonatol 2006; 13: 17-23.
10. Thomas M, Bedford-Russell A, Sharland M. Hospitalisation for RSV infection in ex-preterm infants-implications for use of RSV immune globulin. Arch Dis Child 2000; 83: 122-7.
11. Groothuis JR, Gutierrez KM, Lauer BA. Respiratory syncytial virus infection in children with bronchopulmonary dysplasia. Pediatrics 1988; 82: 199-203.
12. Johnson S, Oliver C, Prince GA, Hemming VG, Pfarr DS, Wang SC, Dormitzer M, O'Grady J, Koenig S, Tamura JK, et al. Development of a humanized monoclonal antibody (MEDI-493) with potent in vitro and in vivo activity against respiratory syncytial virus. J Infect Dis 1997; 176: 1215-24.
13. Young J. Development of a potent respiratory syncytial virus-specific monoclonal antibody for the prevention of serious lower respiratory tract disease in infants. Respir Med 2002; 96: S31-S5.
14. Oh PI, Lanctôt KL, Yoon A, Lee DS, Paes BA, Simmons BS, Parison D, Manzi P; Composs Investigators. Palivizumab prophylaxis for respiratory syncytial virus in Canada: utilization and outcomes. Pediatr Infect Dis J 2002; 21: 512-8.
15. Sorrentino M, Powers T. Effectiveness of palivizumab: evaluation of outcomes from the 1998 to 1999 respiratory syncytial virus season. The Palivizumab Outcomes Study Group. Pediatr Infect Dis J 2000; 19: 1068-71.
16. Frogel M, Nerwen C, Cohen A, VanVeldhuisen P, Harrington M, Boron M; Palivizumab Outcomes Registry Group. Prevention of hospitalization due to respiratory syncytial virus: results from the Palivizumab Outcomes Registry. J Perinatol 2008; 28: 511-7.
17. Parnes C, Guillermin J, Habersang R, Nicholes P, Chawla V, Kelly T, Fishbein J, McRae P, Goessler M, Gatti A, et al.; Palivizumab Outcomes Registry Study Group. Palivizumab prophylaxis of respiratory syncytial virus disease in 2000-2001: results from The Palivizumab Outcomes Registry. Pediatr Pulmonol 2003; 35: 484-9.
18. Saji BT. Indications, efficacy and safety of anti-RS virus monoclonal antibody palivizumab (Synagis) for pediatric patients with congenital heart diseases. J Korean Pediatr Cardiol Soc 2007; 11: 149-50.
19. Lee EA, Jeong JH, Yu ST, Lee CW, Yoon HS, Park DS, Oh YK. Incidence and risk factors of rehospitalization with respiratory syncytial virus infection in premature infants. Korean J Pediatr 2004; 47: 510-4.
20. Palivizumab, a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. The IMpact-RSV Study Group. Pediatrics 1998; 102: 531-7.
21. La Via WV, Notario GF, Yu XQ, Sharma S, Noertersheuser PA, Robbie GJ. Three monthly doses of palivizumab are not adequate for 5-month protection: a population pharmacokinetic analysis. Pulm Pharmacol Ther 2013; 26: 666-71.
22. Kusuda S, Takahashi N, Saitoh T, Terai M, Kaneda H, Kato Y, Ohashi A, Watabe S, Joh-o K, Hirai K. Survey of pediatric ward hospitalization due to respiratory syncytial virus infection after the introduction of palivizumab to high-risk infants in Japan. Pediatr Int 2011; 53: 368-73.
23. Lim JS, Woo SI, Kwon HI, Baek YH, Choi YK, Hahn YS. Clinical characteristics of acute lower respiratory tract infections due to 13 respiratory viruses detected by multiplex PCR in children. Korean J Pediatr 2010; 53: 373-9.
24. Jeong JW, Hwang YH, Cho KS, Jung MJ, Min SK, Kim SJ, Chung WS. Viral etiology and epidemiology of outpatients with acute respiratory illnesses in Busan: 2007-2008. Korean J Pediatr Infect Dis 2010; 17: 130-6.
25. Kim CK, Choi J, Callaway Z, Kim HB, Chung JY, Koh YY, Shin BM. Clinical and epidemiological comparison of human metapneumovirus and respiratory syncytial virus in Seoul, Korea, 2003-2008. J Korean Med Sci 2010; 25: 342-7.
26. Park KH, Shin JH, Lee EH, Seo WH, Kim YK, Song DJ, Choi BM, Choung JT, Hong YS. Seasonal variations of respiratory syncytial virus infection among the children under 60 months of age with lower respiratory tract infections in the capital area, the Republic of Korea, 2008-2011. J Korean Soc Neonatol 2012; 19: 195-203.
27. Chang SG, Park MS, Yu JE. Outcomes of palivizumab prophylaxis for respiratory syncytial virus infection in preterm children with bronchopulmonary dysplasia at a single hospital in Korea from 2005 to 2009. J Korean Med Sci 2010; 25: 251-6.
28. Park SK, Jung YJ, Yoo HS, Ahn SY, Seo HJ, Choi SH, Kim MJ, Jeon GW, Koo SH, Lee KH, et al. Effect of Synagis® (palivizumab) prophylaxis on readmission due to respiratory syncytial virus in very low birth weight infants. Korean J Pediatr 2010; 53: 358-63.
29. Park HW, Lee BS, Kim AR, Yoon HS, Kim BI, Song ES, Kim WT, Lim J, Kim S, Jin HS, et al. Epidemiology of respiratory syncytial virus infection in infants born at less than thirty-five weeks of gestational age. Pediatr Infect Dis J 2012; 31: e99-104.